NKGen Biotech (NKGN)
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on...
- Open
- 0.0051
- High
- 0.0051
- Low
- 0.0051
- Prev. Close
- 0.0051
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- 0.00%
- 52wk High
- 0.3299
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- TradingView · Jul 17 at 04:03 PM
NKGen Biotech Amends $5 Million BDW Loan, Pledging Real Estate as First-Lien Collateral
- StockTitan · Jul 1 at 11:05 PM
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions | NKGN Stock News
- TradingView · May 21 at 04:23 PM
NKGen Biotech Expands AlpineBrook Convertible Loan; Adds $412,500 Note at $0.08 and More Shares
- StockTitan · May 18 at 11:05 PM
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment | NKGN Stock News
- prnewswire · May 5 at 06:38 AM
07:30 ETPackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026
- Tip Ranks · May 4 at 06:16 PM
NKGen Biotech Secures Additional Convertible Financing and Warrants
